Patents by Inventor Julia Maxson

Julia Maxson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF DIAGNOSING AND TREATING aCML and CNL
    Publication number: 20170044625
    Abstract: Disclosed herein are methods and kits used in treating a cancer characterized by aberrant activity of CSF3R. These methods involve detecting a mutation in exon 14 of CSF3R such as a mutation of T615 or T618 and treating the subject with a JAK inhibitor and/or detecting a mutation in exon 17 of CSF3R and treating with dasatinib or tyrosine kinase inhibitor with one or more targets in common with dasatinib.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Jeffrey Tyner, Julia Maxson, Brian Druker
  • METHODS OF DIAGNOSING AND TREATING aCML and CNL
    Publication number: 20140303180
    Abstract: Disclosed herein are methods and kits used in treating a cancer characterized by aberrant activity of CSF3R. These methods involve detecting a mutation in exon 14 of CSF3R such as a mutation of T615 or T618 and treating the subject with a JAK inhibitor and/or detecting a mutation in exon 17 of CSF3R and treating with dasatinib or tyrosine kinase inhibitor with one or more targets in common with dasatinib.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 9, 2014
    Inventors: Jeffrey Tyner, Julia Maxson, Brian Druker
  • METHODS OF DIAGNOSING AND TREATING aCML and CNL
    Publication number: 20140303181
    Abstract: Disclosed herein are methods and kits used in treating a cancer characterized by aberrant activity of CSF3R. These methods involve detecting a mutation in exon 14 of CSF3R such as a mutation of T615 or T618 and treating the subject with a JAK inhibitor and/or detecting a mutation in exon 17 of CSF3R and treating with dasatinib or tyrosine kinase inhibitor with one or more targets in common with dasatinib.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 9, 2014
    Inventors: Jeffrey Tyner, Julia Maxson, Brian Druker